ArticleAntioxidants (Basel, Switzerland)2026
An Efficient Starch-Based Delivery System Ameliorates Naringin's Uptake to Mitigate Acrylamide-Induced Oxidative Stress in Mice.
Article in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Naringin (NAR), a potent antioxidant flavonoid, suffers from low oral bioavailability, limiting its therapeutic application. Here, an efficient octenyl succinic anhydride-modified porous starch (OSAPS) carrier was adopted to enhance NAR's delivery and efficacy against acrylamide (AA)-induced oxidative stress. In Caco-2 cells, the OSAPS-NAR complex demonstrated superior cellular uptake and more effectively mitigated AA-induced cytotoxicity compared to free NAR. Causally, this protection was attributed to its enhanced antioxidant capacity to suppress reactive oxygen species generation, maintain mitochondrial membrane potential, and prevent glutathione (GSH) depletion. Critically, these in vitro advantages translated to remarkable in vivo outcomes. The OSAPS-NAR complex led to a striking 7.91-fold increase in peak plasma concentration and an 11.05-fold increase in relative bioavailability in mice. This enhanced pharmacokinetic profile directly translated to superior antioxidant activities in serum and liver tissues by elevating total antioxidant capacity and GSH content, while simultaneously reducing malondialdehyde levels. These effects collectively led to marked amelioration of AA-induced hepatotoxicity, normalization of the liver index, and restoration of hepatic cellular architecture. In conclusion, the complex effectively overcame NAR's pharmacokinetic limitations, thereby potentiating its ability to modulate cellular redox imbalance and protect against oxidative organ injury. This work provided a robust proof-of-concept for OSAPS-NAR as a promising nutraceutical agent for combating pathologies driven by oxidative stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.